Drug giants pump $40m into Aileron
Cancer treatment drawing interest
Four global pharmaceutical companies have joined in a consortium to provide $40 million in financing to Aileron Therapeutics, a Cambridge biotechnology start-up that is developing a novel approach to treating cancer and other diseases. (Full article: 427 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
